ArticleScientific reports2025
Metabolic and alcohol-related steatotic liver disease and gastrointestinal cancer risk in diabetes.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Structural Characterisation ofMolecules (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We investigated the relationship between incidence of gastrointestinal tract cancers, metabolic dysfunction-associated steatotic liver disease (MASLD), and alcohol-related steatotic liver disease in diabetic population. A nationwide cohort of 2,616,828 individuals with diabetes under Korean National Health Insurance Service from 2015 to 2016 was divided into four subgroups: no steatosis (group 1), MASLD alone (group 2), MASLD with heavy alcohol intake (group 3), and alcoholic liver disease (group 4). We used fatty liver index to assess the probability of hepatic steatosis using cutoff scores of 30 and 60. We analyzed incidences of esophageal, stomach, colorectal, biliary, and pancreatic cancers until 2022. Compared with group 1 (reference), group 2 showed increased hazard ratios for stomach, colorectal, and biliary cancers, with a decreased hazard ratio for esophageal cancer (adjusted hazard ratio [95% confidence interval]: 1.10 [1.06-1.13], 1.13 [1.10-1.16], 1.10 [1.05-1.16], 0.88 [0.79-0.97], respectively). Probability of hepatic steatosis was positively correlated with all gastrointestinal tract cancers except esophageal cancer in non-drinkers, but only with stomach, colorectal, and biliary cancers in mild drinkers (p
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.